Description

Buy Darzalex (Daratumumab) For Sale In USA

Daratumumab (​​Darzalex) is used to treat multiple myeloma to help slow or stop cancer from progressing. Daratumumab is a targeted cancer medicine that binds to a protein on the surface of myeloma cells, it then kills the cancer cells, and also helps the immune system to fight cancer better. It can be used alone as a single therapy but is often used together with other medicines, depending on your clinical situation.

Daratumumab is an infusion that is given into a vein over a period of hours by your healthcare provider. Daratumumab subcutaneous injection is a different product as it contains both daratumumab and hyaluronidase-fihj (Brand name Darzalex Faspro) which is given as an injection under the skin over 3 to 5 minutes.

FDA approval for Daratumumab (Brand name Darzalex) was granted on November 16, 2015, for multiple myeloma patients who had previously had other treatments. Darzalex approval has been extended to treat a range of patients with different treatment regimes. Darzalex Faspro FDA approval was received on May 1, 2023, it is the subcutaneous form of Darzalex.

How does daratumumab work?

Daratumumab mechanism of action (MOA) is by binding to the CD38 protein on the surface of the multiple myeloma cells which it then kills, daratumumab also helps to increase the ability of the immune system to fight cancer. Daratumumab is a monoclonal antibody that is designed to fit together like a lock and key to the antigen CD38 on myeloma cells. It is called a targeted therapy because it specifically targets the CD38  which are overexpressed on the multiple myeloma cells. Daratumumab is from a class of medicines called CD38 monoclonal antibodies.

Daratumumab is not a chemotherapy, it is a targeted cancer medicine.

What is the difference between daratumumab and daratumumab – hyaluronidase-fihj?

The difference between Darzalex and Darzalex Faspro is the number of active ingredients, how they are given, the specific conditions they treat, and the number of systemic administration-related reactions.

• Daratumumab (Darzalex) contains one active ingredient, and is given intravenously over several hours and is used to treat specific multiple myeloma patients.
• Darzalex Faspro contains both daratumumab and hyaluronidase-fihj, and is given subcutaneously over 3 to 5 minutes. Darzalex Faspro is used to treat specific multiple myeloma patients and is also FDA-approved to treat adults with newly diagnosed light chain (AL) amyloidosis. Buy Darzalex (Daratumumab) For Sale In USA
• Darzalex Faspro advantages over Darzalex are that it is faster to administer, it has less systemic administration-related reactions (ARRs), and is also indicated to treat adults with newly diagnosed light chain (AL) amyloidosis as well as adults with certain multiple myeloma.